View : 115 Download: 11

Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis

Title
Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis
Authors
Kim, Mi-SookKim, BongyoungChoi, Jeong PilChoi, Nam-KyongHeo, Jung YeonChoi, Jun YongLee, JoongyubKim, Sang Il
Ewha Authors
최남경
SCOPUS Author ID
최남경scopus
Issue Date
2023
Journal Title
EPIDEMIOLOGY AND HEALTH
ISSN
2092-7193JCR Link
Citation
EPIDEMIOLOGY AND HEALTH vol. 45
Keywords
COVID-19 vaccinesLymphadenopathySelf-controlled case seriesVaccine safety
Publisher
KOREAN SOC EPIDEMIOLOGY
Indexed
SCIE; SCOPUS WOS
Document Type
Article
Abstract
OBJECTIVES: To assess the risk of lymphadenopathy following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination.METHODS: A self-controlled case series design was used to determine whether the risk of lymphadenopathy was higher in the 1-day to 42-day risk interval after coronavirus disease 2019 (COVID-19) vaccination compared to the control period. In addition, subgroup analyses were conducted according to baseline characteristics, time since vaccination, and sensitivity analyses adjusted for the length of the risk interval.RESULTS: The risk of developing lymphadenopathy in the risk interval (1-42 days) after COVID-19 vaccination compared to the control period was significantly increased, with a relative incidence (RI) of 1.17 (95% confidence interval [CI], 1.17 to 1.18) when the first, second, and third doses were combined. The RI was greater on the day of vaccination (1.47; 95% CI, 1.44 to 1.50). In subgroup analyses by baseline characteristics, a significantly increased risk or trend toward increased risk was observed in most subgroups except for those aged 70 years and older, with a significant increase in risk in younger individuals, those with a Charlson's comorbidity index < 5, and those who received mRNA vaccines (mRNA-1273 > BNT162b2). Within the 1-day to 42-day post-dose risk period, the relative risk was highest during the 1-day to 7-day post-dose period (1.59; 95% CI, 1.57 to 1.60) compared to the control period, and then the risk declined. In the sensitivity analysis, we found that the longer the risk window, the smaller the RI.CONCLUSIONS: SARS-CoV-2 vaccination is associated with a statistically significant increase in the risk of lymphadenopathy, and this risk was observed only with mRNA vaccines.
DOI
10.4178/epih.e2023090|http://dx.doi.org/10.4178/epih.e2023090
Appears in Collections:
신산업융합대학 > 융합보건학과 > Journal papers
Files in This Item:
epih-45-e2023090.pdf(351.79 kB) Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE